Aeroseal Secures $67 Million in Series B Funding, Highlighting Private Sector’s Role in Climate Action

In a recent development that suggests increasing buy-in into sustainability efforts, climate-tech firm Aeroseal managed to secure $67 million in its Series B funding round. Given the magnitude of challenges associated with climate change, this investment marks a significant stride in reaffirming the substantial role that private enterprises can play in reducing carbon emissions. Mintz…

Read More

Federal Circuit Ruling Clarifies Patent Law Nuances: Anticipation, Teaching Away, and Commercial Success

In a recent judicial development, the US Court of Appeals for the Federal Circuit has validated the Patent Trial & Appeal Board’s (PTAB) decision to invalidate two patents, signifying essential repercussions in the world of patent law. The ruling imparts that no disparagement does not amount to a “teaching away”, and free samples cannot testify…

Read More

Cannabis Industry Trademark Challenges: Protecting Brands Amid Legal Inconsistencies

Over the past decade, the landscape for recreational cannabis has seen a stark transformation, with many states opting for decriminalization or outright legalization. As these changes have unfolded, however, cannabis businesses find themselves continuing to grapple with protecting their brands. The root of the problem? Federal trademark protection remains elusive for those in the cannabis…

Read More

Impactful Patent Litigation Verdict: Volvo Penta v. Brunswick Reshapes Landscape for Marine Industry

In the week ending August 25, 2023, several key rulings reshaped the landscape of patent litigation. One case particularly stands out: Volvo Penta of the Americas, LLC v. Brunswick Corp., No. 2022-1765 (Fed. Cir. (PTAB) Aug. 24, 2023). The court’s decision addressed a critical issue facing many industries: the challenge of patent claims before the…

Read More

Navigating Terminal Disclaimers and Obviousness-type Double Patenting in Intellectual Property Law

In the realm of intellectual property law, an emerging matter of contention is the nature of Terminal Disclaimers and their potential misuse as an ‘escape hatch’. Terminal Disclaimers, while playing a crucial role in the legal treatment of overlapping patents, are not designed to serve as convenient loopholes in patent law. This issue recently came…

Read More

Federal Circuit Ruling in In re Cellect: Implications for Double Patenting and Patent Term Adjustments

In a recent precedent-setting decision that is already prompting discussion among legal professionals, the U.S. Court of Appeals for the Federal Circuit addressed a longstanding query related to Obvious-Type Double Patenting (ODP) and Patent Term Adjustment (PTA). The Court’s ruling in In re Cellect (No. 22-1293) was promulgated on August 28, 2023. Historically, the relationship…

Read More

USPTO Enhances Transparency and Trust with Domicile Information Requirement in Trademark Applications

In relation to recent requirements that the United States Patent and Trademark Office (USPTO) collect domicile information of all trademark applicants, some clarifications have been made. As required by the Lanham Act, this collection of domicile information is substantial evidence necessary to establish the applicant as a real person or corporation domiciled in the United…

Read More

Federal Circuit Rules Deuterated Derivatives of Ruxolitinib Unpatentable, Impacting Pharmaceutical Patent Landscape

On August 22, 2023, the Federal Circuit made an affirmative decision in an inter partes review (IPR) Final Written Decision, classifying claims to deuterated derivatives of a drug named ruxolitinib as unpatentable due to their obvious nature. The ruling diminished the patentee’s argument that an individual with adequate skills in the field would not have…

Read More

August 2023 Patent Cases: Implications for Intellectual Property in Biomedical and Therapeutic Fields

In August 2023, key decisions were made on a number of patent cases that hold implications for legal professionals in the field of intellectual property, particularly those involved with pharmaceutical and therapeutic patents. One case of note is Incept LLC v. Palette Life Sciences, Inc., (Nos. 2021-2063, -2065 (Fed. Cir. (PTAB) Aug. 16, 2023) The…

Read More

Health Canada’s Statistical Report 2022-2023: Analyzing Trends in Pharmaceutical Regulations and Data Protection

The Office of Patented Medicines and Liaison of Health Canada recently released its Statistical Report for the fiscal year ending March 31, 2023. It encompasses information related to Patented Medicines (Notice of Compliance) Regulations, Data Protection (C.08.004.1 of the Food and Drug Regulations), and Certificates of Supplementary Protection. This document, released on June 23, 2023,…

Read More

PERA 2023: A Turning Point for Medical Diagnostic Patent Eligibility in the US

In a world increasingly dominated by advanced technologies and scientific breakthroughs, determining patent eligibility for innovations has been a longstanding challenge. However, there is now a significant development hinting at the potential simplification of patenting medical diagnostics in the United States. The introduction of the recent bill, the Patent Eligibility Restoration Act of 2023 (PERA),…

Read More

CRISPR Gene Editing Patent Dispute: CVC Files Response and Reply Brief in Ongoing Battle with Broad Institute

In the latest developments, the University of California/Berkeley, the University of Vienna, and Emmanuelle Charpentier (collectively known as “CVC”) have filed their response and reply brief on May 19th in the face of an ongoing consideration by the Patent Trial and Appeal Board (PTAB). This action comes as an appeal against an unfavorable decision on…

Read More

FDA Approves Regeneron’s EYLEA HD® Injection for Eye Conditions: wAMD, DME, and DR Treatment Advances

On August 18, 2023, Regeneron Pharmaceuticals, Inc. announced that the Food and Drug Administration (FDA) granted approval for EYLEA HD®, an 8 mg injection of EYLEA® (aflibercept). The cutting-edge treatment was developed in conjunction with Bayer A.G. and has proven potential in addressing serious eye conditions such as wet age-related macular degeneration (wAMD), diabetic macular…

Read More

Global Food Tech Trademark Expansion: Navigating the Legal Landscape in Alt-Animal Products Market

The increasing consumer demand for alternative animal products, colloquially known as “alt” animal products, has dramatically escalated the number of food tech companies committing to this market. As these entities continue to diversify and build their patent portfolios, they are also focusing on registering trademarks for their company names and alt-animal products across multiple jurisdictions….

Read More

Lewis Silkin Acquires Miller Sturt Kenyon, Expanding Global IP Legal Services

In a strategic move to expand internationally, Lewis Silkin, a leading law firm in the U.K., has acquired the intellectual property firm, Miller Sturt Kenyon (MSK). Known for its prominence in patent and trademark services, MSK extends its services across multiple regions including Germany, France, Belgium, and England. By this purchase, Lewis Silkin, traditionally focusing…

Read More